# Allcyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allcyte

- Industry: Biotechnology
- Headquarters: Vienna, Austria
- Website: www.allcyte.com
- Total disclosed funding: $6M
- Latest round: Seed (Jul 1, 2020)
- Investors on record: 5

## About

Based in Austria, Allcyte GmbH specializes in innovative software solutions that enhance business operations across sectors, focusing on efficiency and productivity through advanced technologies.Allcyte GmbH, founded in 2017 and headquartered in Vienna, Austria, develops software solutions aimed at various industries. The company was acquired in June 2021 by Exscientia Ltd. for EUR 50 million in cash and stock, marking a significant business transaction. The founder, Giulio Superti-Furga, has a background in biotechnology and has been involved in other ventures in this field. Allcyte has completed a total of 3 deals since its inception.Allcyte GmbH specializes in advanced software platforms designed to streamline operational processes for businesses across healthcare, finance, and retail sectors. Its solutions enhance efficiency through features such as data analytics, automated reporting, and customer relationship management, serving a diverse client base that includes both SMEs and large corporations. The company has successfully entered markets in North America, Western Europe, and parts of Asia, offering tailored services to meet local needs.Allcyte generates revenue primarily through a subscription-based model, providing clients access to its software on an ongoing basis. This model fosters long-term relationships with clients through annual or monthly subscriptions. The company also collaborates with industry-specific resellers and consultants to expand its market reach, utilizing a B2B approach. While specific pricing details are not disclosed, the revenue structure accommodates various tiers for clients based on their operational needs and budgets, positioning Allcyte for consistent revenue generation with continual support and updates.Looking ahead, Allcyte GmbH plans to leverage recent funding from its acquisition to enhance its software offerings and expand into new geographic markets. Specific new product launches are in the pipeline, although release dates are not disclosed. The company aims to target additional markets in Asia and North America by 2023, as it seeks to capitalize on its innovative solutions and increased investment support. The EUR 50 million raised from the recent acquisition will be pivotal in driving these expansion and product development initiatives.

## Funding rounds

- Seed, Jul 1, 2020, $6M — VP Capital, PUSH Ventures, 42Cap, Air Street Capital, Amino Collective

## Investors

- VP Capital (https://capitalatlas.ai/funds/vp-capital) — Seed
- PUSH Ventures (https://capitalatlas.ai/funds/push-ventures) — Seed
- 42Cap (https://capitalatlas.ai/funds/42cap) — Seed
- Air Street Capital (https://capitalatlas.ai/funds/air-street-capital) — Seed
- Amino Collective (https://capitalatlas.ai/funds/amino-collective) — Seed